![](/img/cover-not-exists.png)
Cost-effectiveness of imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia
Shelby D. Reed, Kevin J. Anstrom, Jennifer A. Ludmer, G. Alastair Glendenning, Kevin A. SchulmanVolume:
101
Year:
2004
Language:
english
Pages:
10
DOI:
10.1002/cncr.20694
File:
PDF, 119 KB
english, 2004